NY-DILIGENT
27.5.2021 19:09:08 CEST | Business Wire | Press release
Diligent Corporation , the global leader in SaaS governance, risk and compliance, today announced the addition of four new partners, all based in Spain – Esade Center for Corporate Governance , Fundación Woman Forward , Instituto de Gobernanza Empresarial and WomenCEO – in its growing Modern Leadership initiative, which was created to further increase diverse representation in global businesses at the executive and board levels.
These organizations are committed to promoting best corporate governance practices, including increasing diversity and inclusion. According to research conducted by the Diligent Institute , men currently hold approximately three times more board leadership positions than women. The Modern Leadership initiative, which seeks to improve this statistic, helps companies measure and report on diversity as a part of their environmental, social and governance strategy.
“Esade’s Center for Corporate Governance is deeply passionate about the role women play in business success and growth,” said Mario Lara, Director of Esade Madrid and the Center for Corporate Governance. “Progress in achieving equality at the board and senior leadership levels is still nowhere near the rate it should be, which is why global initiatives like Diligent’s Modern Leadership are vital in changing the landscape and trajectory for women leaders.”
The new Spanish organizations joining the Modern Leadership initiative include:
- Esade Center for Corporate Governance - The Center for Corporate Governance together with the Esade Alumni Club of Directors aims to become a leading reference center in the field of corporate governance in Spain. The Esade alumni network is the largest in Europe and one of the most expansive in the world, comprising over 60,000 members in 118 countries.
- Fundación Woman Forward - The foundation is a non-profit institution that promotes women empowerment, gender equality, and diversity, using training and research. Woman Forward encourages and helps to strengthen the role of women in business.
- Instituto de Gobernanza Empresarial - The Institute of Business Governance provides training and networking opportunities, and disseminates research to promote a business culture that is committed to corporate governance.
- WomenCEO - WomenCEO aims to make women visible in the boardroom while demonstrating the need for them to be counted on in economic and social spheres. The organization believes that women are influential, both on the board of directors and in management positions in companies and institutions.
“Closing the gender gap in leadership is a global challenge that we have a greater chance to solve with international coordination,” said Brian Stafford, CEO of Diligent. “This is why expanding Diligent’s Modern Leadership initiative to include these organizations and others like them is imperative. Together, we can use our networks to identify, present and fill leadership positions for diverse candidates in the region and beyond.”
Diligent is committed to driving diversity by enacting change at the board level. To learn more about Diligent’s Modern Leadership initiative, please visit https://diligentmodernleadership.com .
About Diligent Corporation
Diligent is the largest governance, risk and compliance (GRC) SaaS provider, serving more than one million users from over 25,000 organizations around the globe. Our modern GRC platform ensures boards, executives and other leaders have a holistic, integrated view of audit, risk, information security, ethics and compliance across the organization.
Diligent brings technology, insights and confidence to leaders so they can build more effective, equitable and successful organizations. We empower 79% of the Fortune 500, 90% of the FTSE 100 and 83% of the ASX 200 to improve their bottom line, to keep pace with stakeholder expectations and to create a lasting, positive impact on the world.
For more information, visit www.diligent.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005765/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
